z-logo
open-access-imgOpen Access
SENSITIVITY OF HUMAN TUMORS WITH VARIOUS EXPRESSION OF RECAF RECEPTOR TO AFP-CONTAINING COMPLEX OF AIMPILA IN VIVO
Author(s) -
G. P. Smirnova,
С А Цуркан,
Yu. A. Borisova,
J. R Tcherkassova,
В. И. Романенко,
М С Калишьян,
H. M. Treshalina
Publication year - 2017
Publication title -
rossijskij onkologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2412-9119
pISSN - 1028-9984
DOI - 10.18821/1028-9984-2017-22-5-288-291
Subject(s) - in vivo , apoptosis , receptor , transplantation , liver cancer , cancer , colorectal cancer , medicine , cancer research , in vitro , chemistry , biology , biochemistry , microbiology and biotechnology
Experimental studies were carried out with non-covalent complex AIMPILA targeting on AFP receptors (ReCAF). The human subcutaneous xenografts were used with different ReCAF containing transplanted to immunodeficient mice Balb/c nude: colon cancer SW620/ReCAF +, liver cancer HepG2/ReCAF + + and breast cancer T47D/ReCAF + + +. IMPILA was administrated per os under beginning on 4th day after tumor transplantation daily for 5 or 10 days in the total doses of 0.5-2.0 mg/kg or 1.0-4.0 mg/kg, accordingly. The inhibiting effect (T/C < 42%) of AIMPILA was shown to increase in dependence on ReCAF containing on tumor cells: T/C = 70% (SW620/ReCAF +); T/C = 51% (HepG2/ReCAF + +) and T/C = 22% (T47D/ReCAF+++). On the more sensitive model in a series of experiences 10-times course for the treatment with the total dose of 4.0 mg/kg was detected and revealed to T/C = 15-37% (p < 0.05). In the pathomorphological investigation of the T47D/ReCAF+++ tumor there was verified the death of the majority of tumor cells under the treatment of AIMPILA via the apoptosis pathway.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here